<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD000069.pub2" GROUP_ID="MENSTR" ID="528599090814541764" MERGED_FROM="" MODIFIED="2008-11-10 03:50:44 +0100" MODIFIED_BY="Jane Clarke" NOTES="&lt;p&gt;Exported from Review Manager 4.3 Beta&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Short title (no longer in use): Subfertility:unexplained:danazol&lt;/p&gt;&lt;p&gt;&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2008-11-10 15:48:41 +1300" NOTES_MODIFIED_BY="Jane Clarke" REVIEW_NO="253" REVMAN_SUB_VERSION="5.0.16" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="5.0">
<COVER_SHEET MODIFIED="2008-11-10 15:48:41 +1300" MODIFIED_BY="Jane Clarke">
<TITLE>Danazol for unexplained subfertility</TITLE>
<CONTACT>
<PERSON ID="5323" ROLE="AUTHOR">
<PREFIX>A/Prof</PREFIX>
<FIRST_NAME>Edward</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Hughes</LAST_NAME>
<SUFFIX/>
<POSITION>Professor</POSITION>
<EMAIL_1>hughese@mcmaster.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Obstetrics and Gynaecology</DEPARTMENT>
<ORGANISATION>McMaster University</ORGANISATION>
<ADDRESS_1>1200 Main St West</ADDRESS_1>
<ADDRESS_2>Room 4D14</ADDRESS_2>
<CITY>Hamilton</CITY>
<ZIP>L8N 3Z5</ZIP>
<REGION>Ontario</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>+1 905 521 2100 ext: 76563</PHONE_1>
<PHONE_2/>
<FAX_1>+1 905 577 0471</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2008-11-10 15:48:41 +1300" MODIFIED_BY="Jane Clarke">
<PERSON ID="5323" ROLE="AUTHOR">
<PREFIX>A/Prof</PREFIX>
<FIRST_NAME>Edward</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Hughes</LAST_NAME>
<SUFFIX/>
<POSITION>Professor</POSITION>
<EMAIL_1>hughese@mcmaster.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Obstetrics and Gynaecology</DEPARTMENT>
<ORGANISATION>McMaster University</ORGANISATION>
<ADDRESS_1>1200 Main St West</ADDRESS_1>
<ADDRESS_2>Room 4D14</ADDRESS_2>
<CITY>Hamilton</CITY>
<ZIP>L8N 3Z5</ZIP>
<REGION>Ontario</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>+1 905 521 2100 ext: 76563</PHONE_1>
<PHONE_2/>
<FAX_1>+1 905 577 0471</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="6034200E82E26AA200991D564912EB85" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Julie</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Brown</LAST_NAME>
<SUFFIX/>
<POSITION>Cochrane Sytematic Reviewer</POSITION>
<EMAIL_1>j.brown@auckland.ac.nz</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Obstetrics and Gynaecology</DEPARTMENT>
<ORGANISATION>University of Auckland</ORGANISATION>
<ADDRESS_1>FMHS</ADDRESS_1>
<ADDRESS_2/>
<CITY>Auckland</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="NZ">New Zealand</COUNTRY>
<PHONE_1>+64 9 3737599</PHONE_1>
<PHONE_2/>
<FAX_1>+64 9 3035969</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="D32EF03F82E26AA20080535FCD6EC33B" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>G</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Tiffin</LAST_NAME>
<SUFFIX/>
<POSITION>Dr</POSITION>
<EMAIL_1/>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>O&amp;G</DEPARTMENT>
<ORGANISATION>c/o Cochrane Menstrual Disorders &amp; Subfertility</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Auckland</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="NZ">New Zealand</COUNTRY>
<PHONE_1>+6493737599</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2008-11-07 21:12:38 +1300" MODIFIED_BY="Jane Clarke" NOTES="&lt;p&gt;Minor update: 11/15/00&lt;/p&gt;&lt;p&gt;New studies sought but none found: 11/14/06&lt;/p&gt;&lt;p&gt;Reformatted: 11/14/06&lt;/p&gt;" NOTES_MODIFIED="2008-11-07 21:12:38 +1300" NOTES_MODIFIED_BY="Jane Clarke">
<UP_TO_DATE>
<DATE DAY="15" MONTH="11" YEAR="2006"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="14" MONTH="11" YEAR="2006"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="14" MONTH="11" YEAR="2008"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="1996"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="1996"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2007"/>
</DATES>
<WHATS_NEW MODIFIED="2008-11-10 15:44:55 +1300" MODIFIED_BY="jane clarke" NOTES="&lt;p&gt;The text and tables of this review have been updated and amended in line with the MDSG style.&lt;/p&gt;" NOTES_MODIFIED="2008-11-10 15:44:55 +1300" NOTES_MODIFIED_BY="jane clarke">
<WHATS_NEW_ENTRY EVENT="STABLE" MODIFIED="2008-11-10 15:44:55 +1300" MODIFIED_BY="jane clarke">
<DATE DAY="10" MONTH="11" YEAR="2008"/>
<DESCRIPTION>
<P>The MDSG feel that there are unlikely to be any further RCT's in this topic area and therefore this review was closed following its publication Issue 1,2007</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT">
<DATE DAY="7" MONTH="11" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="15" MONTH="11" YEAR="2006"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Ministry of Health</NAME>
<COUNTRY CODE="NZ">New Zealand</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Royal Commission on New Reproductive Technologies</NAME>
<COUNTRY CODE="NONE">Not specified</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-11-10 15:45:37 +1300" MODIFIED_BY="jane clarke">
<SUMMARY MODIFIED="2008-11-10 15:39:42 +1300" MODIFIED_BY="jane clarke">
<TITLE MODIFIED="2008-11-10 15:39:42 +1300" MODIFIED_BY="jane clarke">Danazol for treating subfertility</TITLE>
<SUMMARY_BODY>
<P>The drug danazol (Danocrine) was the most frequently prescribed medication for endometriosis but has also been tested as a treatment for unexplained subfertility. The review of trials found that there is no evidence that low doses of danazol improve live births/ ongoing pregnancy rates. Other negative factors include adverse effects.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2008-11-10 15:43:03 +1300" MODIFIED_BY="jane clarke">
<ABS_BACKGROUND>
<P>The synthetic androgen Danazol, was developed in the 1970's as a treatment for endometriosis. Its use was soon advocated in women with unexplained subfertility. Two randomised trials were subsequently conducted to assess the effectiveness of danazol in this population.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>The objective of this review was to assess the effect of danazol on live birth rate in women with unexplained subfertility.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>We searched the Cochrane Menstrual Disorders and Sub-fertility Group's specialised register of trials (searched November , 2006) the Cochrane Register of Controlled Trials (The Cochrane Library, Issue 4, 2006), MEDLINE (1966-November 2006), EMBASE (1980 - November 2006) and reference lists of articles.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Randomised trials of danazol compared with placebo or no treatment in women with unexplained subfertility.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Data were extracted by two reviewers EH and GT.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2008-11-10 15:43:03 +1300" MODIFIED_BY="jane clarke">
<P>Two trials involving seventy-one women were included. There was no statistically significant difference in the live birth/ ongoing pregnancy rate between danazol and placebo at the end of treatment (OR 1.16, 95% CI 0.0 to 8.29; p=0.36) or at the end of follow-up (OR 2.41; 95% CI 0.59 to 9.82; p=0.22). There was no significant difference in clinical pregnancies following treatment (OR 0.14, 95% CI 0.01 to 2.26; p=0.17), however there were significantly more clinical pregnancies during the follow-up period in the danazol group compared with the placebo group (OR 3.15, 95%CI 0.98 to 10.10; p&lt;0.05). Multiple side effects were reported.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>Available data demonstrate no evidence of the benefit of danazol for unexplained subfertility. Although there is insufficient evidence to be certain of this, the need for contraception during treatment and the adverse effects and costs of danazol, make its use for this problem unwarranted. The increased pregnancy rate in the long term follow-up data may be attributable to additional therapies and did not influence the live birth/ongoing pregnancy data.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-11-10 15:45:37 +1300" MODIFIED_BY="jane clarke">
<BACKGROUND>
<P>Danazol, a synthetic derivative of ethisterone, was originally developed as a treatment for endometriosis. It is administered as an oral tablet. <LINK REF="REF-Kennedy-1990" TYPE="REFERENCE">Kennedy 1990</LINK> summarises that the possible modes of action for Danazol include direct effects on ovarian steroidogenesis (<LINK REF="REF-Olsson-1986" TYPE="REFERENCE">Olsson 1986</LINK>;<LINK REF="REF-Steingold-1986" TYPE="REFERENCE">Steingold 1986</LINK>), endometrial growth (<LINK REF="REF-Rose-1988" TYPE="REFERENCE">Rose 1988</LINK>), and testosterone displacement from sex hormone-binding globulin; the suppression of which results in elevated free testosterone levels (<LINK REF="REF-Nilsson-1983" TYPE="REFERENCE">Nilsson 1983</LINK>). Danazol induced ovarian suppression results in amenorrhoea, endometrial atrophy and improvement in endometriotic lesions. It does however have anabolic and androgenic side effects including weight gain, oily skin, hirsutism, acne (<LINK REF="REF-Burry-1989" TYPE="REFERENCE">Burry 1989</LINK>) and hot flushes, depression, mood swings, changes in libido. The associated side effects prompted the term 'pseudomenopause' for the ovarian suppression resulting from danazol therapy (<LINK REF="REF-Dmowski-1976" TYPE="REFERENCE">Dmowski 1976</LINK>). Its use was advocated in women with unexplained infertility (<LINK REF="REF-Greenblatt-1974" TYPE="REFERENCE">Greenblatt 1974</LINK>). </P>
</BACKGROUND>
<OBJECTIVES>
<P>The objective of this review was to test the hypothesis that danazol is more effective than placebo in the treatment of unexplained subfertility in terms of increasing the live birth/ongoing pregnancy rate.</P>
</OBJECTIVES>
<METHODS MODIFIED="2008-11-10 15:45:05 +1300" MODIFIED_BY="jane clarke">
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>Only randomised trials were considered for inclusion, quasi randomised trials were excluded. <BR/>
</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Participants were women with unexplained subfertility. Unexplained subfertility was defined as a duration of &gt;1 year; tubal patency confirmed by hysterosalpingogram or laparoscopy; ovulation confirmed by a serum progesterone level considered to be in the ovulatory range by the authors, endometrial biopsy showing evidence of secretory change, or regular menstrual cycle of 21 to 42 days duration; semen quality considered normal based on acceptable standard at the time of publication.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Oral danazol in any dose, compared with placebo or no treatment administered for any duration.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<P>Primary outcome measure was live birth/ongoing pregnancies per woman randomised and clinical pregnancies per woman randomised.<BR/>Secondary outcome measures were spontaneous miscarriage, ectopic pregnancies and side effects.</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-11-10 15:45:05 +1300" MODIFIED_BY="jane clarke">
<P>We searched for all publications which describe (or might describe) randomised controlled trials of danazol for unexplained sub-fertility. The original search was performed in 1995 and updated in 1999, 2005 and 2006.</P>
<ELECTRONIC_SEARCHES MODIFIED="2008-11-10 15:45:05 +1300" MODIFIED_BY="jane clarke">
<P>1) We searched the Cochrane Menstrual Disorders and Sub-fertility Group's specialised register of trials (searched November, 2006). See review group details for more details on the make-up of the Specialised Register.</P>
<P>2) The Cochrane Central Register of Controlled Trials (CENTRAL) on The Cochrane Library, Issue 4, 2006 was searched in all fields</P>
<P>3) The following electronic databases were searched using Ovid software using search string see <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>
</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2008-11-10 15:39:02 +1300" MODIFIED_BY="jane clarke">
<P>4) The citation lists of relevant publications, review articles and included studies were also searched.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION>
<P>
<I>S</I>
<I>tudy selection</I>
<BR/>The study selection was undertaken by two reviewers (EH and GT). The titles and abstracts of articles found in the search were screened by EH and GT, who discarded studies that were clearly ineligible. Then EH, and GT independently assessed whether the studies met the inclusion criteria, with disagreements resolved by discussion. Further information was sought from the authors where papers contained insufficient information to make a decision about eligibility. An updated search was conducted in November 2006 by JB.</P>
<P>
<I>A</I>
<I>ssessment of Methodological Quality</I>
<BR/>The quality of all studies that were deemed eligible for the review were assessed independently by the two reviewers (EH and GT), any discrepancies were resolved by discussion. The quality of allocation concealment was graded as adequate (A), unclear (B), or inadequate (C), following the detailed descriptions of these categories provided by the Menstrual Disorders and Subfertility Review Group.</P>
<P>
<I>D</I>
<I>ata and extraction and analysis</I>
<BR/>Data extraction was performed independently by the two reviewers (EH and GT). Discrepancies were resolved by discussion. For each included trial, information was collected regarding the location of the study, methods of the study, the participants (age range, eligibility criteria), the nature of the interventions, and data relating to the outcomes specified above. Where possible, missing data was sought from the authors. </P>
<P>Statistical analysis was performed in accordance with the guidelines for statistical analysis developed by the Cochrane Collaboration. Heterogeneity (variations) between the results of different studies was examined by inspecting the scatter in the data points on the graphs and the overlap in their confidence intervals and, more formally, by checking the results of the chi-squared tests. The I<SUP>2</SUP> statistic for heterogeneity between groups was computed and used. Where possible, the outcomes were pooled statistically.</P>
<P>For dichotomous data, results for each study were expressed as an odds ratio with 95% confidence interval and combined for meta-analysis with RevMan software using the Peto method and a Fixed-effect model. </P>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2008-11-10 15:45:37 +1300" MODIFIED_BY="jane clarke">
<STUDY_DESCRIPTION>
<P>Two small studies were identified (<LINK REF="STD-Iffland-1989" TYPE="STUDY">Iffland 1989</LINK>; <LINK REF="STD-van-Dijk-1979" TYPE="STUDY">van Dijk 1979</LINK>). <LINK REF="STD-van-Dijk-1979" TYPE="STUDY">van Dijk 1979</LINK> included forty women with unexplained subfertility, treating them with Danazol 200 mg or placebo, daily for one hundred days. During this time, contraception does not appear to have been advised, despite the potential adverse effects of danazol during early pregnancy. Follow up was for six months and only pregnancies occurring during that period were included in the analysis. </P>
<P>
<LINK REF="STD-Iffland-1989" TYPE="STUDY">Iffland 1989</LINK> included thirty-nine women with primary unexplained subfertility. Treatment with Danazol 200 mg daily or placebo lasted for three months. Eight women were excluded from analysis because of failure to complete treatment or medical illness. Three further women were withdrawn from the Danazol group during the follow up phase, which lasted twelve months. <LINK REF="STD-Iffland-1989" TYPE="STUDY">Iffland 1989</LINK> reported that nineteen women underwent additional therapies including superovulation, intrauterine artificial insemination, IVF and embryo transfer or gamete intrafallopian transfer post study treatment.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2008-11-10 15:45:37 +1300" MODIFIED_BY="jane clarke">
<P>See <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>. Neither of these studies explicitly stated the method of allocation nor randomisation method used. The high incidence of oligomenorrhoea associate with active treatment makes blinding virtually impossible. One study (<LINK REF="STD-van-Dijk-1979" TYPE="STUDY">van Dijk 1979</LINK>) reported complete follow-up among forty couples, but excluded one patient from the analysis (placebo group) because she conceived during the six month treatment phase, rather than in the six month post-treatment period. This decision undermines the validity of their conclusions. This patient has been included as part of the intention-to treat for the meta-analysis.</P>
<P>A second study [<LINK REF="STD-Iffland-1989" TYPE="STUDY">Iffland 1989</LINK>] described the eight patients who left their trial post randomization, but did not report the pregnancy rate in this group. Interestingly, although side effects were reported with a similar frequency between groups in this study, more women left the Danazol than the placebo group, leaving eleven and seventeen women respectively. Neither trial used a crossover design and co-intervention did not appear to be present.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS>
<P>Two trials involving seventy-one women were included (<LINK REF="STD-Iffland-1989" TYPE="STUDY">Iffland 1989</LINK>; <LINK REF="STD-van-Dijk-1979" TYPE="STUDY">van Dijk 1979</LINK>). There was no statistically significant difference in the live birth/ ongoing pregnancy rate between Danazol and placebo at the end of treatment (OR 1.16, 95% CI 0.0 to 8.29; P=0.36) or at the end of follow-up (OR 2.41; 95% CI 0.59, 9.82; P=0.22). There was no significant difference in clinical pregnancies following treatment (OR 0.14, 95% CI 0.01, 2.26; P=0.17), however there were significantly more clinical pregnancies during the follow-up period in the Danazol group compared with the placebo group (OR 3.15, 95%CI 0.98, 10.10; P&lt;0.05). Multiple side effects were reported by <LINK REF="STD-Iffland-1989" TYPE="STUDY">Iffland 1989</LINK> although no significant differences were observed between treatment and placebo groups. Menstrual irregularities were reported by both papers (<LINK REF="STD-Iffland-1989" TYPE="STUDY">Iffland 1989</LINK>; <LINK REF="STD-van-Dijk-1979" TYPE="STUDY">van Dijk 1979</LINK>) with significantly more women reporting menstrual irregularities and amenorrhoea in the Danazol group compared to placebo (OR13.60; 95%CI 4.96, 37.31; P&lt;0.0001).<BR/>
</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>These studies are limited by their small sample size and lack of methodological quality. The results indicated no evidence of benefit of Danazol over placebo on live births/ongoing pregnancies. The significant effect on clinical pregnancies in the long term follow up may be attributable to the use of additional therapies which women had undergone in that time period. The significant effect of menstrual irregularities is a treatment effect although the statistical heterogeneity in the studies is high (I<SUP>2</SUP> = 77.9%). <BR/>When the evidence of lack of treatment effect and the known adverse effects of Danazol, including weight gain, acne and hirsutism are considered, it is the authors opinion that Danazol cannot be recommended in women with unexplained subfertility.</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>There is no evidence of benefit of Danazol in women with unexplained subfertility. </P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>Larger trials do not appear to be warranted based on these findings.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>The review authors wish to acknowledge the support of the MDSG for their help and support.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>Julie Brown was involved in the most recent update of this review October 2006. She ran the latest electronic search and updated the style of the review to the the MDSG standards.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2008-11-10 15:44:03 +1300" MODIFIED_BY="jane clarke">
<P>The search has been revised</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES>
<P>The MDSG feel that there are unlikely to be any further RCT's in this topic area and therefore this review will be closed following its publication Issue 1,2007</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES>
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Iffland-1989" NAME="Iffland 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Iffland CA, Shaw RW, Beynon JL</AU>
<TI>Is danazol a useful treatment in unexplained primary infertility?</TI>
<SO>European Journal Obstetric Gynecological Reproductive Biology</SO>
<YR>1989</YR>
<VL>32</VL>
<PG>115-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-van-Dijk-1979" NAME="van Dijk 1979" YEAR="1979">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van Dijk JG, Frolich M, Brand EC, van Hall EV</AU>
<TI>The treatment of unexplained infertility with danazol</TI>
<SO>Fertility and Sterility</SO>
<YR>1979</YR>
<VL>31</VL>
<PG>481-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Need-1992" NAME="Need 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Need JA, Forbes KL, Milazzo L, McKenzie E</AU>
<TI>Danazol in the treatment of menorrhagia: The effect of a 1 month induction dose (200 mg) and 2 month's maintenance therapy (200 mg, 100 mg, 50 mg or placebo)</TI>
<SO>Australian New Z ealand Journal Obstetrics and Gynaecology</SO>
<YR>1992</YR>
<VL>32</VL>
<PG>346-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES>
<ADDITIONAL_REFERENCES>
<REFERENCE ID="REF-Burry-1989" NAME="Burry 1989" TYPE="JOURNAL_ARTICLE">
<AU>Burry K, Patton P, Illingworth D</AU>
<TI>Metabolic changes during medical treatment of endometriosis: Nafarelin acetate versus danazol</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1989</YR>
<VL>160</VL>
<NO>6</NO>
<PG>1454-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dmowski-1976" NAME="Dmowski 1976" TYPE="BOOK_SECTION">
<AU>Dmowski W, Scommegna A</AU>
<TI>The rationale for treatment of endometriosis with dananzol</TI>
<SO>Recent Advances in Endometriosis. Proceedings of a Symposium. Amsterdam</SO>
<YR>1976</YR>
<PG>99</PG>
<ED>Greenblatt R</ED>
<PB>Excerpta Medica</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Greenblatt-1974" NAME="Greenblatt 1974" TYPE="JOURNAL_ARTICLE">
<AU>Greenblatt RB, Borenstein R, Ayup H</AU>
<TI>Experiences with danazol (an antigonadotrophin) in the treatment of infertility</TI>
<SO>American Journal Obstetrics and Gynecology</SO>
<YR>1974</YR>
<VL>118</VL>
<PG>783</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kennedy-1990" NAME="Kennedy 1990" TYPE="JOURNAL_ARTICLE">
<AU>Kennedy S, Williams I, Brodribb J, Barlow D, Shaw R</AU>
<TI>A comparison of nafarelin acetate and danazol in the treatment of endometriosis</TI>
<SO>Fertility and Sterility</SO>
<YR>1990</YR>
<VL>53</VL>
<NO>6</NO>
<PG>998-1003</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nilsson-1983" NAME="Nilsson 1983" TYPE="JOURNAL_ARTICLE">
<AU>Nilsson B, Sodergard R, Damber M, Damber J, von Schoultz B</AU>
<TI>Free testosterone levels during danazol therapy</TI>
<SO>Ferility and Sterility</SO>
<YR>1983</YR>
<VL>39</VL>
<PG>505</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Olsson-1986" NAME="Olsson 1986" TYPE="JOURNAL_ARTICLE">
<AU>Olsson J, Hillensjo T, Nilsson L</AU>
<TI>Inhibitory effects of danazol on steroidogenesis in cultured human granulosa cells</TI>
<SO>Fertility and Sterility</SO>
<YR>1986</YR>
<VL>46</VL>
<PG>237</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rose-1988" NAME="Rose 1988" TYPE="JOURNAL_ARTICLE">
<AU>Rose G, Dowsett M, Mudge J, White J, Jeffcoate S</AU>
<TI>The inhibitory effects of danazol, danazol metabolites, gestrinone, and testosterone on the growth of human endometrial cells in vitro</TI>
<SO>Fertility and Sterility</SO>
<YR>1988</YR>
<VL>49</VL>
<PG>224</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Steingold-1986" NAME="Steingold 1986" TYPE="JOURNAL_ARTICLE">
<AU>Steingold KA, Lu JKH, Judd HL, Meldrum DR</AU>
<TI>Danazol inhibits steroidogenesis by the human embryo in vivo</TI>
<SO>Fertility and Sterility</SO>
<YR>1986</YR>
<VL>45</VL>
<PG>649</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Iffland-1989">
<CHAR_METHODS>
<P>Random allocation. Method not stated. No details of allocation concealment. Double blind design. Attrition was 8/39 see quality table for details.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>UK study. 39 women with primary unexplained subfertility. Women were aged 20-38, mean age Danazol group 30.8 +/- 3.3, placebo group 30.9 +/- 3.5 years. Inclusion criteria were for no known endocrine disorder, regular menstrual cycles, ovulating, normal laparoscopy at least 6 months prior to study entry, +ve post coital test. Normal semen analysis and no variocoele in male partner. No other details of exclusion.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Danazol 200 mg daily for 12 weeks, n=14 patients <BR/>vs<BR/>Placebo one tablet daily for 12 weeks, n=17 patients </P>
<P>Long term follow up for up to 36 months.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Pregnancy<BR/>Haematologic and liver function tests<BR/>Side effects<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-van-Dijk-1979">
<CHAR_METHODS>
<P>Random allocation. Method not stated. No details of concealment. There was an attempt to blind the women to treatment allocation but investigators were aware of which treatment arm women were in as study progressed. Attrition was 1/40 see quality table for details.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Dutch study. Participants were 40 women with unexplained infertility (primary and secondary); BBT, luteal serum progesterone, HSG, normal semen, PCT. <BR/>Median age of placebo group was 29.5 (range 26-37), and of Danazol group was 30 (range 27-38 years).<BR/>Only women who had undergone laparoscopy at least 6 months earlier were included.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Danazol 200 mg orally daily for 6 months, n=21 <BR/>vs<BR/>Placebo one tablet daily for 6 months, n=19 <BR/>Women were followed up for six months at 2 monthly intervals.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Pregnancy <BR/>FSH, LH, prolactin, estradiol, progesterone, side effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Author's analysis excludes 1 pregnancy in the placebo group; this has been included as ITT in this meta-analysis. Follow-up duration was 6 months</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Need-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Study of danazol for menorrhagia. Pregnancy data not recorded.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Iffland-1989">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-van-Dijk-1979">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2008-11-10 15:42:50 +1300" MODIFIED_BY="jane clarke">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2008-11-10 15:42:50 +1300" MODIFIED_BY="jane clarke" NO="1">
<TITLE MODIFIED="2008-11-10 15:42:50 +1300" MODIFIED_BY="jane clarke">Risk of bias table</TITLE>
<TABLE COLS="7" ROWS="3">
<TR>
<TH>
<P>Study ID</P>
</TH>
<TH>
<P>Randomisation</P>
</TH>
<TH>
<P>Concealment</P>
</TH>
<TH>
<P>Power</P>
</TH>
<TH>
<P>Intent-to Treat</P>
</TH>
<TH>
<P>Attrition</P>
</TH>
<TH>
<P>Funding</P>
</TH>
</TR>
<TR>
<TD>
<P>Iffland 1989</P>
</TD>
<TD>
<P>No details of randomisation method</P>
</TD>
<TD>
<P>No details of allocation concealment</P>
</TD>
<TD>
<P>No details</P>
</TD>
<TD>
<P>No details</P>
</TD>
<TD>
<P>Eight women excluded. Six failed to start or complete the treatment , 1 was diagnosed as a diabetic and 1 with hypothyroidism</P>
</TD>
<TD>
<P>Winthrop laboratories, UK</P>
</TD>
</TR>
<TR>
<TD>
<P>Van Dijk 1979</P>
</TD>
<TD>
<P>No details of randomisation method</P>
</TD>
<TD>
<P>No details of allocation concealment</P>
</TD>
<TD>
<P>No details</P>
</TD>
<TD>
<P>No details, 1 pregnancy in the placebo group during treatment was excluded from the analysis but has been included as the ITT population in this meta-analysis</P>
</TD>
<TD>
<P>n=1, one woman was excluded due to pregnancy in the placebo group</P>
</TD>
<TD>
<P>No details</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2008-11-10 15:42:08 +1300" MODIFIED_BY="jane clarke">
<COMPARISON ID="CMP-001" MODIFIED="2008-11-10 15:42:08 +1300" MODIFIED_BY="jane clarke" NO="1">
<NAME>Danazol versus placebo in unexplained subfertility</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="8.288624577540523" CI_START="0.0031449953559810943" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.16145490331307902" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.9184824692784819" LOG_CI_START="-2.502379991513871" LOG_EFFECT_SIZE="-0.7919487611176945" METHOD="PETO" MODIFIED="2008-11-10 15:41:32 +1300" MODIFIED_BY="jane clarke" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.3641502758598495" Q="0.0" RANDOM="NO" SCALE="673.2033981746009" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="14" TOTAL_2="17" WEIGHT="100.0" Z="0.9074852129730303">
<NAME>Live birth/ongoing pregnancies per woman randomised following treatment</NAME>
<GROUP_LABEL_1>Danazol</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>danazol</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.288624577540526" CI_START="0.003144995355981091" EFFECT_SIZE="0.16145490331307902" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9184824692784821" LOG_CI_START="-2.5023799915138714" LOG_EFFECT_SIZE="-0.7919487611176945" ORDER="96728" O_E="-0.45161290322580644" SE="2.00943154301171" STUDY_ID="STD-Iffland-1989" TOTAL_1="14" TOTAL_2="17" VAR="0.2476586888657648" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.4186750845619374" CI_END="9.823645848664153" CI_START="0.5923078218019302" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="2.412182056722883" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" I2="29.511696449593817" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.9922726973696386" LOG_CI_START="-0.2274525321860239" LOG_EFFECT_SIZE="0.3824100825918073" METHOD="PETO" MODIFIED="2008-11-10 15:41:40 +1300" MODIFIED_BY="jane clarke" NO="2" P_CHI2="0.23362184122577578" P_Q="1.0" P_Z="0.21907869295041227" Q="0.0" RANDOM="NO" SCALE="147.71866978267903" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="35" TOTAL_2="36" WEIGHT="100.0" Z="1.2289816936523832">
<NAME>Live births/ongoing pregnancies per woman randomised during treatment and follow up</NAME>
<GROUP_LABEL_1>Danazol</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>danazol</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.357835668449743" CI_START="0.21721703593331088" EFFECT_SIZE="1.264218040839888" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.8667500839731659" LOG_CI_START="-0.663106116828616" LOG_EFFECT_SIZE="0.10182198357227507" ORDER="96729" O_E="0.2903225806451615" SE="0.898645105261295" STUDY_ID="STD-Iffland-1989" TOTAL_1="14" TOTAL_2="17" VAR="1.238293444328824" WEIGHT="63.56569386826549"/>
<DICH_DATA CI_END="76.26126790927498" CI_START="0.7270782559205169" EFFECT_SIZE="7.446335317843465" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.8823040215175648" LOG_CI_START="-0.13841884321879303" LOG_EFFECT_SIZE="0.8719425891493859" ORDER="96730" O_E="1.425" SE="1.1869826134856392" STUDY_ID="STD-van-Dijk-1979" TOTAL_1="21" TOTAL_2="19" VAR="0.7097596153846154" WEIGHT="36.43430613173451"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.009862758435467078" CI_END="2.25959082208277" CI_START="0.008695503973982163" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.14017232598838597" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.35402980206760737" LOG_CI_START="-2.060705242094089" LOG_EFFECT_SIZE="-0.8533377200132408" METHOD="PETO" MODIFIED="2008-11-10 15:41:46 +1300" MODIFIED_BY="jane clarke" NO="3" P_CHI2="0.9208910109444811" P_Q="1.0" P_Z="0.16597468531174633" Q="0.0" RANDOM="NO" SCALE="662.600470427028" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="35" TOTAL_2="36" WEIGHT="100.0" Z="1.3852544211169209">
<NAME>Pregnancy per woman randomised following treatment</NAME>
<GROUP_LABEL_1>Danazol</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>danazol</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.288624577540526" CI_START="0.003144995355981091" EFFECT_SIZE="0.16145490331307902" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9184824692784821" LOG_CI_START="-2.5023799915138714" LOG_EFFECT_SIZE="-0.7919487611176945" ORDER="96731" O_E="-0.45161290322580644" SE="2.00943154301171" STUDY_ID="STD-Iffland-1989" TOTAL_1="14" TOTAL_2="17" VAR="0.2476586888657648" WEIGHT="49.82734458722991"/>
<DICH_DATA CI_END="6.169229351845254" CI_START="0.0024052528556907766" EFFECT_SIZE="0.1218136138366199" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.7902309161978239" LOG_CI_START="-2.618839261053621" LOG_EFFECT_SIZE="-0.9143041724278985" ORDER="96732" O_E="-0.525" SE="2.0025046972870353" STUDY_ID="STD-van-Dijk-1979" TOTAL_1="21" TOTAL_2="19" VAR="0.249375" WEIGHT="50.17265541277009"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.17902004520516346" CI_END="10.104341224116844" CI_START="0.9802834053720694" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="3.1472397468605156" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="1.0045080039416516" LOG_CI_START="-0.008648349209790499" LOG_EFFECT_SIZE="0.4979298273659305" METHOD="PETO" MODIFIED="2008-11-10 15:41:52 +1300" MODIFIED_BY="jane clarke" NO="4" P_CHI2="0.6722167597143276" P_Q="1.0" P_Z="0.05404156030122931" Q="0.0" RANDOM="NO" SCALE="26.733304264610936" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="35" TOTAL_2="36" WEIGHT="100.0" Z="1.9265032991795172">
<NAME>Pregnancies per woman randomised during treatment and follow up</NAME>
<GROUP_LABEL_1>Danazol</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>danazol</GRAPH_LABEL_2>
<DICH_DATA CI_END="12.224698644600577" CI_START="0.508089632451307" EFFECT_SIZE="2.4922364737646983" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="1.087238161979691" LOG_CI_START="-0.29405966676088185" LOG_EFFECT_SIZE="0.3965892476094045" ORDER="96733" O_E="1.3870967741935485" SE="0.811381182136739" STUDY_ID="STD-Iffland-1989" TOTAL_1="14" TOTAL_2="17" VAR="1.518973291710024" WEIGHT="53.79950575077806"/>
<DICH_DATA CI_END="22.97339355909685" CI_START="0.7424247781861413" EFFECT_SIZE="4.12989305155659" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.361225152579942" LOG_CI_START="-0.12934754210986002" LOG_EFFECT_SIZE="0.6159388052350409" ORDER="96734" O_E="1.85" SE="0.8755697793146265" STUDY_ID="STD-van-Dijk-1979" TOTAL_1="21" TOTAL_2="19" VAR="1.304423076923077" WEIGHT="46.20049424922194"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="167.8595251454447" CI_START="0.5816730949407388" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="9.881263558201129" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="2.224945990211587" LOG_CI_START="-0.23532102385678824" LOG_EFFECT_SIZE="0.9948124831773995" METHOD="PETO" MODIFIED="2008-11-10 15:41:56 +1300" MODIFIED_BY="jane clarke" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.11295986444226214" Q="0.0" RANDOM="NO" SCALE="266.42139489720637" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="14" TOTAL_2="17" WEIGHT="100.0" Z="1.5850284763801439">
<NAME>Miscarriage per woman randomised</NAME>
<GROUP_LABEL_1>Danazol</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>danazol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="167.8595251454447" CI_START="0.5816730949407388" EFFECT_SIZE="9.881263558201129" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.224945990211587" LOG_CI_START="-0.23532102385678824" LOG_EFFECT_SIZE="0.9948124831773995" ORDER="96735" O_E="1.096774193548387" SE="1.445173022581896" STUDY_ID="STD-Iffland-1989" TOTAL_1="14" TOTAL_2="17" VAR="0.47880679847381197" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="117.50088105622343" CI_START="0.42457296823286816" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="7.063122386028573" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="2.0700411230879383" LOG_CI_START="-0.37204766000755507" LOG_EFFECT_SIZE="0.8489967315401915" METHOD="PETO" MODIFIED="2008-11-10 15:42:03 +1300" MODIFIED_BY="jane clarke" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.17295491799494175" Q="0.0" RANDOM="NO" SCALE="164.13303109847587" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="21" TOTAL_2="19" WEIGHT="100.0" Z="1.3627702877384935">
<NAME>Ectopic pregnancy per woman randomised</NAME>
<GROUP_LABEL_1>Danazol</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>danazol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="117.50088105622334" CI_START="0.42457296823286833" EFFECT_SIZE="7.063122386028573" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.070041123087938" LOG_CI_START="-0.37204766000755496" LOG_EFFECT_SIZE="0.8489967315401915" ORDER="96736" O_E="0.95" SE="1.4344950397247302" STUDY_ID="STD-van-Dijk-1979" TOTAL_1="21" TOTAL_2="19" VAR="0.48596153846153844" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="33.01031197390812" CI_END="3.6662262733173763" CI_START="1.1235373824781214" CI_STUDY="95" CI_TOTAL="95" DF="7.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="2.0295670155714305" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="26" I2="78.79450516695233" I2_Q="78.9309021658333" ID="CMP-001.07" LOG_CI_END="0.5642192653781263" LOG_CI_START="0.05058752689656155" LOG_EFFECT_SIZE="0.30740339613734396" METHOD="PETO" MODIFIED="2008-11-10 15:42:08 +1300" MODIFIED_BY="jane clarke" NO="7" P_CHI2="2.635972338449477E-5" P_Q="7.636296152557787E-5" P_Z="0.018974213143522163" Q="28.47772622836322" RANDOM="NO" SCALE="139.56307878456846" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="119" TOTAL_2="138" WEIGHT="700.0" Z="2.346037209210031">
<NAME>Adverse events/side effects</NAME>
<GROUP_LABEL_1>Danazol</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>danazol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.289913517263581" CI_START="0.1675791581876347" DF="0.0" EFFECT_SIZE="0.7425098906635194" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" I2="0.0" ID="CMP-001.07.01" LOG_CI_END="0.5171844816980402" LOG_CI_START="-0.7757799955323897" LOG_EFFECT_SIZE="-0.1292977569171747" NO="1" P_CHI2="1.0" P_Z="0.6950606042182574" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="17" WEIGHT="100.0" Z="0.39199676604002054">
<NAME>Skin changes</NAME>
<DICH_DATA CI_END="3.289913517263581" CI_START="0.1675791581876347" EFFECT_SIZE="0.7425098906635194" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.5171844816980402" LOG_CI_START="-0.7757799955323897" LOG_EFFECT_SIZE="-0.1292977569171747" ORDER="96737" O_E="-0.516129032258065" SE="0.7594937342025392" STUDY_ID="STD-Iffland-1989" TOTAL_1="14" TOTAL_2="17" VAR="1.7336108220603537" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.5755866653785753" CI_START="0.008925019093439918" DF="0.0" EFFECT_SIZE="0.15161517129005606" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" ID="CMP-001.07.02" LOG_CI_END="0.41087616794691756" LOG_CI_START="-2.049390846121458" LOG_EFFECT_SIZE="-0.8192573390872702" NO="2" P_CHI2="1.0" P_Z="0.19178473410007021" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="17" WEIGHT="100.0" Z="1.305317568783648">
<NAME>Headache/migraine</NAME>
<DICH_DATA CI_END="2.5755866653785753" CI_START="0.008925019093439918" EFFECT_SIZE="0.15161517129005606" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.41087616794691756" LOG_CI_START="-2.049390846121458" LOG_EFFECT_SIZE="-0.8192573390872702" ORDER="96738" O_E="-0.9032258064516129" SE="1.445173022581896" STUDY_ID="STD-Iffland-1989" TOTAL_1="14" TOTAL_2="17" VAR="0.47880679847381197" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="33.61909436082967" CI_START="0.7642876453923002" DF="0.0" EFFECT_SIZE="5.068989886482322" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" I2="0.0" ID="CMP-001.07.03" LOG_CI_END="1.526586010132845" LOG_CI_START="-0.1167431606705755" LOG_EFFECT_SIZE="0.7049214247311347" NO="3" P_CHI2="1.0" P_Z="0.09266781955942453" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="17" WEIGHT="100.0" Z="1.6814897817802565">
<NAME>Abdominal bloating/discomfort</NAME>
<DICH_DATA CI_END="33.61909436082965" CI_START="0.7642876453923003" EFFECT_SIZE="5.068989886482322" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.5265860101328446" LOG_CI_START="-0.11674316067057543" LOG_EFFECT_SIZE="0.7049214247311347" ORDER="96739" O_E="1.7419354838709675" SE="0.9652996895405178" STUDY_ID="STD-Iffland-1989" TOTAL_1="14" TOTAL_2="17" VAR="1.0731876517516474" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.5755866653785753" CI_START="0.008925019093439918" DF="0.0" EFFECT_SIZE="0.15161517129005606" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" ID="CMP-001.07.04" LOG_CI_END="0.41087616794691756" LOG_CI_START="-2.049390846121458" LOG_EFFECT_SIZE="-0.8192573390872702" NO="4" P_CHI2="1.0" P_Z="0.19178473410007021" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="17" WEIGHT="100.0" Z="1.305317568783648">
<NAME>Tender breasts</NAME>
<DICH_DATA CI_END="2.5755866653785753" CI_START="0.008925019093439918" EFFECT_SIZE="0.15161517129005606" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.41087616794691756" LOG_CI_START="-2.049390846121458" LOG_EFFECT_SIZE="-0.8192573390872702" ORDER="96740" O_E="-0.9032258064516129" SE="1.445173022581896" STUDY_ID="STD-Iffland-1989" TOTAL_1="14" TOTAL_2="17" VAR="0.47880679847381197" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.532585745544896" CI_END="37.309955629742234" CI_START="4.955529571369118" DF="1.0" EFFECT_SIZE="13.597447864568458" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="2" I2="77.93753817050442" ID="CMP-001.07.05" LOG_CI_END="1.5718247325634889" LOG_CI_START="0.6950900720673159" LOG_EFFECT_SIZE="1.1334574023154023" NO="5" P_CHI2="0.03325538543644657" P_Z="4.025473139905536E-7" STUDIES="2" TAU2="0.0" TOTAL_1="35" TOTAL_2="36" WEIGHT="100.0" Z="5.067749198580275">
<NAME>Oligomenorrhea/amenorrhoea</NAME>
<DICH_DATA CI_END="16.49947971389286" CI_START="0.4870954230823046" EFFECT_SIZE="2.8349287560495315" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.2174702496110024" LOG_CI_START="-0.31238595119077966" LOG_EFFECT_SIZE="0.45254214921011127" ORDER="96741" O_E="1.2903225806451615" SE="0.898645105261295" STUDY_ID="STD-Iffland-1989" TOTAL_1="14" TOTAL_2="17" VAR="1.238293444328824" WEIGHT="32.84241843544514"/>
<DICH_DATA CI_END="100.3162160586721" CI_START="8.541352740530204" EFFECT_SIZE="29.27176432933893" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="0" LOG_CI_END="2.001371142148605" LOG_CI_START="0.9315266577175112" LOG_EFFECT_SIZE="1.4664488999330583" ORDER="96742" O_E="8.55" SE="0.6284319459704324" STUDY_ID="STD-van-Dijk-1979" TOTAL_1="21" TOTAL_2="19" VAR="2.5321153846153845" WEIGHT="67.15758156455486"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.3288526359499215" CI_START="0.2630432457374778" DF="0.0" EFFECT_SIZE="1.2902565400549069" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" I2="0.0" ID="CMP-001.07.06" LOG_CI_END="0.8013249834705853" LOG_CI_START="-0.5799728452699875" LOG_EFFECT_SIZE="0.11067606910029901" NO="6" P_CHI2="1.0" P_Z="0.7534579721589056" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="17" WEIGHT="99.99999999999999" Z="0.31408303824647965">
<NAME>Weight gain</NAME>
<DICH_DATA CI_END="6.3288526359499215" CI_START="0.2630432457374778" EFFECT_SIZE="1.2902565400549069" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.8013249834705853" LOG_CI_START="-0.5799728452699875" LOG_EFFECT_SIZE="0.11067606910029901" ORDER="96743" O_E="0.3870967741935485" SE="0.811381182136739" STUDY_ID="STD-Iffland-1989" TOTAL_1="14" TOTAL_2="17" VAR="1.518973291710024" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5552510265967547" CI_START="0.0926691653777261" DF="0.0" EFFECT_SIZE="0.3796364242108138" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="9" I2="0.0" ID="CMP-001.07.07" LOG_CI_END="0.19180049668576238" LOG_CI_START="-1.0330647484225075" LOG_EFFECT_SIZE="-0.42063212586837256" NO="7" P_CHI2="1.0" P_Z="0.17825538747788694" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="17" WEIGHT="100.0" Z="1.346146150746004">
<NAME>Other reported side effects</NAME>
<DICH_DATA CI_END="1.5552510265967552" CI_START="0.0926691653777261" EFFECT_SIZE="0.3796364242108138" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="9" LOG_CI_END="0.19180049668576252" LOG_CI_START="-1.0330647484225075" LOG_EFFECT_SIZE="-0.42063212586837256" ORDER="96744" O_E="-1.870967741935484" SE="0.7194919081573469" STUDY_ID="STD-Iffland-1989" TOTAL_1="14" TOTAL_2="17" VAR="1.9317377731529657" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES MODIFIED="2008-11-10 15:37:48 +1300" MODIFIED_BY="jane clarke">
<APPENDIX ID="APP-01" MODIFIED="2008-11-10 15:37:48 +1300" MODIFIED_BY="jane clarke" NO="1">
<TITLE MODIFIED="2008-11-10 15:37:45 +1300" MODIFIED_BY="jane clarke">Search string</TITLE>
<APPENDIX_BODY MODIFIED="2008-11-10 15:37:48 +1300" MODIFIED_BY="jane clarke">
<P>MEDLINE (1966-November 2006)<BR/>EMBASE (1980 - November 2006 )</P>
<P>1 (unexplained adj3 infertil$).mp.<BR/>2 (unexplained adj3 subfertil$).mp.<BR/>3 (idiopathic adj3 infertil$).mp.<BR/>4 (idiopathic adj3 subfertil$).mp.<BR/>5 or/1-4<BR/>6 danazol.mp. or exp DANAZOL/<BR/>7 5 and 6<BR/>8 randomized controlled trial.pt.<BR/>9 controlled clinical trial.pt.<BR/>10 randomized controlled trials/<BR/>11 random allocation/<BR/>12 double-blind method/<BR/>13 single-blind method/<BR/>14 or/8-13<BR/>15 clinical trial.pt.<BR/>16 exp clinical trials/<BR/>17 (clin$ adj25 trial$).ti,ab,sh.<BR/>18 ((singl$ or doubl$ or tripl$ or trebl$) adj25 (blind$ or mask$)).ti,ab,sh.<BR/>19 placebos/<BR/>20 placebo$.ti,ab,sh.<BR/>21 random$.ti,ab,sh.<BR/>22 research design/<BR/>23 or/15-22<BR/>24 animal/ not (human/ and animal/)<BR/>25 14 or 23<BR/>26 25 not 24<BR/>27 7 and 26</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>